Company intelligence / Profile preview
Freedom Biosciences
San Francisco, California, United Statesfreedombio.co ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
The lead program FREE001 showed 3x longer duration of antidepressant effect than ketamine & esketamine in proof-of-concept studies: 14-21 days of antidepressant effects vs. 2-7 days for ketamine and esketamine. The company is entering Phase 2a (n=120) trials in Q2 2024[7].
- Therapeutic areas
- Psychiatry
- Modalities
- Ketamine-based therapeuticsPsychedelic-based therapeutics
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
Yale University
Beyond the preview
Go deeper on Freedom Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Freedom Biosciences.